First Author: M.Vinkovic CROATIA
Co Author(s): G. De Salvo D. Bosnar T. Benasic A. Kopic
Back to previous
To determine the efficacy of combined intravitreal bevacizumab and triamcinolone in the treatment of macular oedema due to retinal vein occlusion.
University Hospital Osijek, Retina Department
Prospective randomised trial including 51 patients divided into three arms. Subjects in the first arm received 1.25 mg intravitreal bevacizumab, those in the second arm underwent injection of 1 mg intravitreal triamcinolone, while those in the third received both drugs in the same day. Patients had visual acuity, intraocular pressure, spectral domain optical coherence tomography and fundus fluorescein angiography at baseline and follow-up.
The major reduction in central macular thickness was seen in those patients who received the combined treatment. There was no statistically significant intraocular pressure elevation among subjects in the different treatment arms. A positive trend in terms of visual improvement was seen in the arm that received the combined treatment despite the lowest initial visual acuity, the thicker macular thickness and the longest duration of the symptoms.
Combined treatment with bevacizumab and triamcinolone for macular oedema secondary to retinal vein occlusions allows for fewer injections and it is more potent, safe, efficient and cost-effective than bevacizumab or triamcinolone alone.